Literature DB >> 21994111

Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection.

Donald R Shaffer1, Andrea M Sheehan, Zhongzhen Yi, Cheryl C Rodgers, Catherine M Bollard, Malcolm K Brenner, Cliona M Rooney, Helen E Heslop, Stephen Gottschalk.   

Abstract

Severe chronic active Epstein-Barr virus infection (CAEBV) in T or NK cells is a rare complication of latent EBV infection. CAEBV associated T-cell lymphoproliferative disease (LPD) consists of polyclonal lesions as well as aggressive lymphomas. Here, we report such a patient. In addition, we show that this primary CAEBV associated T-cell lymphoma expresses CD70 and is sensitive to killing by CD70-specific T cells, identifying CD70 as a potential immunotherapeutic target for CAEBV-associated T-cell lymphoma.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21994111      PMCID： PMC3258475          DOI： 10.1002/pbc.23352

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  18 in total

1.  Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

Authors:  Julie A McEarchern; Ezogelin Oflazoglu; Leigh Francisco; Charlotte F McDonagh; Kristine A Gordon; Ivan Stone; Kerry Klussman; Eileen Turcott; Nico van Rooijen; Paul Carter; Iqbal S Grewal; Alan F Wahl; Che-Leung Law
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

2.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

3.  Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation.

Authors:  T Okamura; Y Hatsukawa; H Arai; M Inoue; K Kawa
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

4.  Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection.

Authors:  K Kawa; A Sawada; M Sato; T Okamura; N Sakata; O Kondo; T Kimoto; K Yamada; S Tokimasa; M Yasui; M Inoue
Journal:  Bone Marrow Transplant       Date:  2010-05-24       Impact factor: 5.483

5.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

6.  Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome.

Authors:  K Ohshima; J Suzumiya; M Sugihara; S Nagafuchi; S Ohga; M Kikuchi
Journal:  Pathol Int       Date:  1998-12       Impact factor: 2.534

7.  Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation.

Authors:  Kensei Gotoh; Yoshinori Ito; Yukiko Shibata-Watanabe; Jun-ichi Kawada; Yoshiyuki Takahashi; Hiroshi Yagasaki; Seiji Kojima; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

Review 8.  Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.

Authors:  Koichi Ohshima; Hiroshi Kimura; Tadashi Yoshino; Chul Woo Kim; Young H Ko; Seung-Suk Lee; Suat-Cheng Peh; John K C Chan
Journal:  Pathol Int       Date:  2008-04       Impact factor: 2.534

9.  Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells.

Authors:  Masanori Baba; Mika Okamoto; Takayuki Hamasaki; Sawako Horai; Xin Wang; Yuji Ito; Yasuo Suda; Naomichi Arima
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

10.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113
View more
  1 in total

Review 1.  The CD70-CD27 axis in oncology: the new kids on the block.

Authors:  Tal Flieswasser; Astrid Van den Eynde; Jonas Van Audenaerde; Jorrit De Waele; Filip Lardon; Carsten Riether; Hans de Haard; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.